Delivery Order SPE2DB20D3104-SPE2DB21FW0F8
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a total ceiling value of $3,784.10 and is a Firm Fixed Price Delivery Order that runs through October 24, 2023. The contract is for the delivery of Humulin R 500 Unit/ML KwikPen 3ML, a pharmaceutical product, to support military and federal healthcare programs. Amerisourcebergen Drug Corp is the prime...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Humulin R 500 Unit/mL Kwikpen 3mL. The $10,628.96 firm-fixed price delivery order falls under a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive...
- This federal contract award, valued at $9,695.64, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Humulin R 500 unit/mL KwikPen 3mL medication. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. The contract has no set-aside designation, indicating it was competed on an open basis. Amerisourcebergen Drug Corp holds a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Humulin R 500 Unit/mL KwikPen 3mL. The contract is a Delivery Order with a Firm Fixed Price pricing type, valued at $2,250.66. It has an Ultimate Completion Date of October 15, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. Both companies are for-profit...
- This federal contract award is to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation, to provide Humulin R 500 unit/mL KwikPen 3mL to the Defense Logistics Agency (DLA). The firm fixed price delivery order has a potential value of $2,236.93 and a period of performance through February 8, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation. This order is being issued under Amerisourcebergen...
- This federal contract award, valued at $19,168.96, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HUMULIN R 500 UNIT/ML KWIKPEN 3ML, a specialty pharmaceutical product. The award was made as a firm-fixed-price delivery order contract, with a completion date of November 22, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc.,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Humulin R 500 Unit/mL Kwikpen 3mL. The $2,247.60 firm fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., through the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive...
- This federal contract award is for the delivery of Humulin R 500 unit/ml Kwikpen 3ml, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider that is a subsidiary of the parent company Cencora, Inc. The contract, valued at $5,626.65, is a firm fixed-price delivery order with a completion date of November 12, 2021. It is not designated as a set-aside...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Humulin R 500 Unit/ML KwikPen 3 ML. The contract has a ceiling value of $11,434.47 and is a Firm Fixed Price Delivery Order with an ultimate completion date of August 15, 2024. The contract is not set aside for any specific business type. As a large pharmaceutical supplier, Amerisourcebergen has been awarded numerous Indefinite...
- This federal contract award is for the delivery of Humulin R 500 unit/mL KwikPen 3mL to the Defense Logistics Agency (DLA) by the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has a ceiling value of $4,495.20 and an ultimate completion date of August 15, 2023. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating it was awarded through open competition. Amerisourcebergen Drug Corp is a major...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB21FW0F8Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of Humulin R 500 unit/mL KwikPen 3mL. The contract, valued at $3,375.99, is a Firm Fixed Price Delivery Order with a completion date of September 29, 2021. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also does business as Amerisourcebergen. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, for the delivery of a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. Additionally, Cencora, Inc. maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/28/21 |